Sentence examples for favourable risk from inspiring English sources

The current commercially available GBCA with the most favourable risk profile in terms of NSF and cerebral deposition is the macrocyclic ionic agent gadoterate meglumine.

Compared to ergot alkaloids (ergotamine, dihydroergotamine and methysergide), that are non-specific serotonin type 1 (5-HT1) receptor agonists as they target also 5-HT2, andenergic andopaminergicic receptors, triptans act as selective agonists at 5-HT1B and 5-HT1D subtypes, displaying a more favourable risk profile to ergots [27, 28].

In this review, we aim to summarize the progress made in the gene therapy trials targeting ADA-SCID, SCID-X1, CGD and WAS, review the pitfalls, and outline the recent advancements which are expected to further enhance favourable risk benefit ratios for gene therapeutic approaches in the future.

This is supported by the fact that patients with less favourable risk factor profiles at baseline (worse prognosis) are more likely to be lost to follow-up.

In the earlier years, younger patients with a more favourable risk profile presented for interdisciplinary consultation.

To achieve a more favourable risk profile, changes in diet and lifestyle are needed.

Tui is our preferred tour operator, as we think it offers a more favourable risk-reward balance than Thomas Cook, and we like its scope for margin recovery and specialist holiday expansion.

He says pension funds have been advised to move into hedge funds by consultants, who are impressed by hedge funds' favourable risk-return trade-offs.The problem, says Mr Naik, is that the consultants had to rely on past data.

Drug regulatory agencies in various countries attempt to rely on premarketing scientific studies of the effects of drugs in animals and humans in order to determine if new drugs have a favourable risk-to-benefit ratio.

PEGylation and increasing the specific activity enhance the pharmacokinetic properties of a 177Lu-labelled BN-based radiopharmaceutical and provide a protocol for targeted radionuclide therapy with a beneficial anti-tumour effectiveness and a favourable risk-profile at the same time.

On the basis of the ease of use and lack of AE concerns associated with nVNS in the current study, the device appears to have a favourable risk-benefit profile in MM/MRM that is appropriate for further evaluation.